Targeted delivery of nanomedicines for promoting vascular regeneration in ischemic diseases

Theranostics. 2022 Aug 29;12(14):6223-6241. doi: 10.7150/thno.73421. eCollection 2022.

Abstract

Ischemic diseases, the leading cause of disability and death, are caused by the restriction or blockage of blood flow in specific tissues, including ischemic cardiac, ischemic cerebrovascular and ischemic peripheral vascular diseases. The regeneration of functional vasculature network in ischemic tissues is essential for treatment of ischemic diseases. Direct delivery of pro-angiogenesis factors, such as VEGF, has demonstrated the effectiveness in ischemic disease therapy but suffering from several obstacles, such as low delivery efficacy in disease sites and uncontrolled modulation. In this review, we summarize the molecular mechanisms of inducing vascular regeneration, providing the guidance for designing the desired nanomedicines. We also introduce the delivery of various nanomedicines to ischemic tissues by passive or active targeting manner. To achieve the efficient delivery of nanomedicines in various ischemic diseases, we highlight targeted delivery of nanomedicines and controllable modulation of disease microenvironment using nanomedicines.

Keywords: ischemic diseases; nanomedicines; targeted delivery; theranostics; vascular regeneration.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inducing Agents
  • Drug Delivery Systems
  • Humans
  • Nanomedicine
  • Nanoparticles*
  • Neoplasms* / drug therapy
  • Tumor Microenvironment
  • Vascular Endothelial Growth Factor A

Substances

  • Angiogenesis Inducing Agents
  • Vascular Endothelial Growth Factor A